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finalized with input from principal investigators. Results: More than 2900 publica-
tions and 300 websites were screened, and 16 registries, 17 cohort studies and 43 data-
bases were reviewed. Nine data sources from seven countries were recommended, 
of which six complementary sources were included: Get With The Guidelines-Stroke 
in the USA (an in-hospital database including about 1600 hospitals); National Stroke 
Registry in China (132 hospitals); Fukuoka Stroke Registry in Japan (seven stroke 
centres); Clinical Research Centre for Stroke – 5thDivision Registry in South Korea 
(12 stroke centres); Riks-Stroke in Sweden (all Swedish hospitals admitting patients 
with acute stroke); and Erlangen Stroke Registry in Germany (Erlanger community). 
Based on a globally agreed study design concept, protocols for each data source have 
been developed locally and are now being implemented. ConClusions: The ARES 
programme will provide global, observational data from contemporary populations 
with mild stroke/TIA in real-world clinical practice. Studies will be presented individu-
ally owing to differences in the nature of the data sources.
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objeCtives: Health Technology Assessment of innovative biomedical devices still 
requires the effort to introduce dedicated Information Technology tools able to 
support the implementation of the evaluation process. The aim of the study was 
to systematize the collection, the management and the analysis of large volumes 
of multidimensional data in order to optimally conduct an HTA study of emerg-
ing technologies. Methods: We designed a relational database, subsequently we 
developed and implemented a centralized, web-based user-friendly data entry for 
Case Report Form (CRF) data collection. (i) The development of User Interface (UI), 
(ii) data anonymization, (iii) differentiate accesses, (iv) automated quality control 
checks for data entry, (v) appropriate system tables to make data entry uniform, and 
(vi) the possibility of creating final reports were addressed. In the data extraction 
phase, we used MySQL computer languages and combined PHP and HTML codes. 
Knowledge Discovery in Data process was implemented with different software 
and programming languages for automation of the data collection, extraction and 
analysis. Results: The IT tools have been applied to the first multicenter prospec-
tive Italian study of HTA on the da Vinci surgical system, obtaining meaningful end 
points in terms of costs and clinical outcomes. The study involved the enrolment of 
699 patients from the 8 Italian Teaching Hospitals in the period 2011-2014. Patients 
were enrolled and prospectively evaluated from the preoperative work-up till six 
months after the discharge. ConClusions: The IT tools developed allow research-
ers to more efficiently and effectively manage large volumes of various source of 
HTA data, enhancing data quality from storage to processing. The database design 
could be empowered and readjusted for other HTA studies in near future and the 
entire approach generalized. In the immature field of HTA of innovative biomedical 
devices, this example of application could promote the automation of the imple-
mentation process of HTA.
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objeCtives: The primary objective is to describe how patients with advanced STS 
are managed in France. The secondary objectives are to describe the epidemiologi-
cal characteristics, the diagnostic procedures as well as the therapeutic strategy for 
the management of patients with STS. Methods: This observational, retrospective 
and national study will use the patient databases of the European CONTICANET 
“CONnective TIssue Cancer NETwork” network and of the French networks: RRePS 
and NetSarc(Pathological and Clinical Reference Networks for Soft Tissues and 
Visceral Sarcomas) . All the data collected in these networks and compiled in the 
“Sarcoma clinicobiological database” will allow good national representativity of 
STS. The study period was defined to reflect the current situation in terms of diagno-
sis and disease management in France. Results: The European database currently 
contains data from 12,485 patients (pts) registered by the French Sarcoma Group 
centers with 9,736 soft tissues and visceral sarcomas. Data from STS patients, who 
were diagnosed between 2012 and 2013, will be extracted from the Conticabase 
database. Part of these data will be “chained” with the shared database from the 
French networks RRePS (24,000 pts) and NetSarc (28,000 pts). Results are expected at 
the end of 2015. ConClusions: This pharmacoepidemiological study shows how 
useful high-quality medical databases are to study rare diseases and their manage-
ment in real life. This study is carried out as part of a public/private partnership.
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objeCtives: Due to high prevalence of socially significant chronic diseases among 
children the introduction of information technologies in the process of interac-
tion between doctor and patient is important. The aim: to analyze the prospects 
of the development of remote monitoring systems, to identify their shortcomings 
and to propose solutions. Methods: The review had included 36 publications, 1 
meta-analysis concerning telemedicine from 2001 to 2014 y. In the evaluated studies 
the following questions were explored: • research of social and economic aspects of 
The updated version of Charlson Comorbidity Index (CCI), for predicting resource 
utilisation, was never considered in such studies.
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objeCtives: The randomized clinical trials (RCT), as gold standard for evidence-
based medicine, have a number of shortcomings, and their results do not fully 
reflect actual clinical practice. In cases where RCTs are difficult to conduct because 
of ethical or other aspects, data bases of clinical cases - medical registries are used 
to determine the effectiveness and safety of any medical intervention in long-
term observation. Due to heterogeneity of clinical symptoms in different groups 
of patients with bronchial asthma (BA), to assess the efficacy and safety of treat-
ment of severe persistent uncontrolled asthma in the real clinical practice, the best 
practice is to use a long-term clinical monitoring. Aim - to create patient registry 
for children and adolescents with severe persistent uncontrolled BA. Methods: 
By experts of center in the result of system work software was created. It was shell 
for management of database of clinical cases – patient registry of children with 
uncontrolled severe persistent BA, who received Omalizumab as addition to basis 
therapy. Results: The database included information about 64 children (62.5% 
boys) from 6 to 17 y 11 mo (mean age 12.9 y) with severe persistent uncontrolled 
BA, who received / receive (31 patients, 70.9% boys) bioengineered treatment (dura-
tion of treatment from 1 till 70 mo). During the analyzed period of treatment safety 
of Omalizumab was confirmed: more than 5384 injections were conducted. Local 
adverse events were registered at frequency of 1/100 and were manifested as light 
redness, induration and light edema, were realized in 1-1.5 days after Omalizumab 
administration. Local allergic reactions such as rash were observed in two patients 
and were stopped by antihistamines ConClusions: The patient registry will help 
in solving problems as epidemiological, and in order to achieve optimal endpoints 
for monitoring and analysis of efficacy and safety of innovative high-tech medica-
tions and approaches which have been used previously for long time.
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objeCtives: Since 2012, the Italian Medicines Agency (AIFA-Agenzia Italiana del 
Farmaco), with the cooperation of CliCon, has been providing and updating the 
OsMed Health-DB Database, a nationwide standardized monitoring system to pro-
vide analyses, reports, and trends on appropriateness of medicines’ use and medica-
tion persistence, to inform decision-makers in order to improve health outcomes 
and to avoid wasting of health-care resources Methods: The OsMed Health-DB 
Database has two main components with distinct but complementary functions: a 
data-warehouse, a repository containing the integrated demographic, pharmaceuti-
cal and hospital discharges administrative data kept by Local Health Units (LHUs) 
and Regional Health Units (RHUs) and a dashboard, a set of performance indicators, 
with updates scheduled every six months, evaluating the prescription adherence 
to preset standards of some chronic pathologies at the local, regional, and national 
level. In 2014, 36 LHUs and 5 RHUs provided data, covering all Italian Regions and 
the data-warehouse stored information of about 30 million patients (almost the 
50.0% of the entire Italian population). Results: The 2014 OsMed Report reported 
the trend of 34 indicators on appropriateness and adherence of 10 chronic diseases: 
hypertension, hypercholesterolemia, diabetes mellitus, COPD, osteoporosis, depres-
sion, ulcers and esophagitis, anemia, psoriasis and rheumatoid arthritis. The average 
age of the LHU sample resulted 44.0 years versus 43.7 years of the Italian popula-
tion. The percentage of males resulted 48.5%, in accordance with the national data 
available. Medication persistence rate for all studied diseases averaged 43.3%, with a 
range of 13.9% of respiratory system drugs and 62.2% of anti-diabetic drugs. Results 
will be reported on “National Report on medicines use in Italy” available at AIFA 
website. ConClusions: Findings from the OsMed Health-DB Database highlighted 
that the majority of indicators is changing toward appropriateness and adherence. 
These findings prove that continuous monitoring of appropriateness and adherence 
is a driver for improving real-world use of medicines.
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objeCtives: Patients with mild stroke or transient ischaemic attack (TIA) are at 
high risk of recurrent stroke and other cardiovascular events. The Assessment of 
Real-world Evidence in Stroke/TIA (ARES) programme aims to characterize the 
management and outcomes of patients with mild stroke/TIA in real-world clinical 
practice using the most suitable data sources. Methods: In an initial Systematic 
Understanding of Real-world Evidence (SURE) assessment, suitable data sources 
(cohorts, registries and databases) were identified and characterized by systematic 
literature and web searches supplemented with e-mail and telephone contact. Data 
sources were recommended if they were active, representative, accessible, recorded 
National Institutes of Health Stroke Scale (NIHSS) scores or ABCD2 scores, and 
reported health resource utilization, ischaemic events and death during follow-up of 
at least 90 days (either direct or via linkage). The programme of included studies was 
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objeCtives: Health economic models typically follow a Markovian framework with 
discrete health states. The transition probability matrix (TPM), which characterizes 
the health state transitions, is the key driver of such a model. Estimation of TPM 
depends upon the observation intervals of clinical studies and the model cycle 
length. Generally Maximum-Likelihood (ML) or eigen-decomposition method can 
be used to estimate the TPM. However, these methods are not feasible for stud-
ies with non-uniform observation intervals (e.g., observations taken at 1, 3 & 6 
months), or when eigenvalues are negative or complex. The current objective is to 
provide a generalized algorithm to estimate TPM in all possible situations using 
all the available data. Methods: Craig & Sendi (2002) illustrated an EM algorithm 
approach to estimate 1 month TPM for a 3-state model, where 1 and 2 month obser-
vations were available. We generalized this procedure and created an algorithm 
for any observation intervals and any number of states. We evaluated this algo-
rithm in the following situations: i) Observations at multiple intervals to estimate 
a single cycle TPM, ii) Seventh month observed transitions to estimate a 2-month 
TPM when the eigenvalues are complex, iii) Sixth month observed transitions to 
estimate a 2-month TPM when the eigenvalues are negative. Results: The gen-
eralized EM algorithm approach replicated results obtained from ML and eigen-
decomposition method. In cases where eigenvalues were negative and complex, 
this method provided solutions which were valid and interpretable. In all three 
situations mentioned above, the generalized EM algorithm produced consistent and 
valid results. ConClusions: A generalized EM algorithm can be a useful tool to 
estimate TPM, in complex situations where ML estimation and eigen-decomposition 
cannot be used. It allows the use of all the observed data to estimate the TPM, thus 
increasing the accuracy of the health economic models.
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objeCtives: To assess how suitable current COPD cost-effectiveness models are to 
evaluate personalized treatment options for COPD by exploring the type of hetero-
geneity included in current models and by validating outcomes for subgroups of 
patients. Methods: A consortium of COPD modelling groups participated in three 
evaluations. First, they reported all patient characteristics included in the model and 
provided the level of detail in which the input parameters were specified. Second, 
groups simulated disease progression, mortality, QALYs and costs for hypotheti-
cal subgroups of patients that differed in gender, age, smoking status and FEV1% 
predicted. Finally, model outcomes for exacerbations and mortality for subgroups 
of patients were validated against published subgroup results of two large COPD 
trials. Results: Nine COPD modelling groups participated. Most models included 
gender (7), age (9), smoking status (6) and FEV1% predicted (9), mainly to specify 
disease progression and mortality. Almost all input parameters were specified by 
FEV1% predicted. In addition, disease progression was higher for females and smok-
ers in three and five models, respectively and costs were higher for older patients 
in three models. Differences between subgroups on other parameters were more 
variable between the models. Trial results showed higher exacerbation rates for 
females, which was found in one model, higher mortality rates for males (found 
in two models), lower mortality for younger patients (found in four models), and 
higher exacerbation and mortality rates in severe COPD compared to moderate 
COPD patients (found in four models). ConClusions: The majority of currently 
available COPD cost-effectiveness models are able to evaluate the cost-effectiveness 
of personalized treatment based on gender, age, smoking and FEV1% predicted. 
Treatment in COPD is however, more likely to be personalized based on clinical 
parameters. Two models include several clinical patient characteristics and seem 
most suitable to evaluate personalized treatment, although some important clinical 
parameters are still missing.
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objeCtives: To estimate the number of prevalent cases of abdominal aortic aneu-
rysm (AAA) and deaths attributable to AAA in five major European Union (5EU) 
markets: France, Germany, Italy, Spain, and the United Kingdom (UK). Methods: 
We used disease modeling software, DisMod II (World Health Organization), to 
assess AAA burden via a multi-state life table where differential equations define 
relationships between incidence, prevalence, and disease-specific mortality. 
Market-specific input data included age- and sex-specific population structure, 
age- and sex-specific all-cause mortality, and cubic spline interpolation of size- 
and sex-specific AAA prevalence. Other input data consisted of relative risk (RR) 
estimates of death for persons with AAA compared with persons without AAA, 
adjusted for age, ethnicity, height, weight, smoking, and cardiovascular disease 
history. Results: We estimated 2,484,058 prevalent cases in the 5EU in 2013 (90% 
CI: 2,282,702–2,638,106), resulting in 48,805 deaths attributable to AAA (90% CI: 
39,924–54,291). In the combined 5EU, females accounted for 20.2% of prevalent 
cases and 43.2% of deaths. France had the lowest number of prevalent cases 
(581.8 per 100,000 population) and deaths (11.0 per 100,000 population) among 
the 5EU markets, while Italy had the highest number of prevalent cases (1,103.7 
per 100,000 population) and deaths (22.3 per 100,000 population). The number of 
telemedicine (evaluation of usefulness); • the view of information systems or archi-
tectures. The following characteristics were taken: • purpose of the system; • inter-
action of patients and physicians; • training and impact on lifestyle - the formation 
of health-preserving behaviors (with the exception of smoking, adequate physical 
activity, etc.); • self-management. Results: The following problems of implemen-
tation of telemedicine systems were identified: • high cost, the need to purchase 
special equipment and devices; • the need for training and motivation of both staff 
and patients; • lack of a unified architecture, protocol stack and hardware-software 
platform for the integration of systems at all stages of the process - from data collec-
tion to its processing, decision-making and patient feedback. Despite the fair amount 
of existing telemonitiring systems almost all of its provide only data collection, while 
the entire analytical part falls on the doctor. Almost all of studies were focused on the 
elderly and adults. ConClusions: A promising direction is the development of a 
prototype system for remote health monitoring in pediatric patients. The study was 
supported by the Russian Foundation for Basic Research, the project ¹ 13-04-12055.
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objeCtives: Real-world big data accessible through electronic health record (EHR) 
systems offer opportunities to collect generalizable information to populate eco-
nomic models. Using a supervised machine learning approach, the objectives 
were: (a) to mine a hospital EHR for transition probabilities of high-risk patients 
for developing hospital-acquired pressure ulcers (HAPUs); and (b) to compare 
efficiency and accuracy of predictive methods between Markov modeling and 
Bayesian inference with EHR data. Methods: This study used a de-identified 
panel of patient hospitalizations since 2010 in a U.S. tertiary academic medi-
cal center EHR to study Braden scores of patient risk for developing HAPUs. The 
study focused on patients hospitalized for ≥ 5 days and at least two Braden scores. 
Braden scores were converted from an ordered scale into five categories (i.e. mini-
mal risk; at risk; moderate risk; high risk; very high risk). A 10-stage Markov model 
was constructed via supervised machine learning using R software designating 
the five Braden categories as transition states, as well as end-states for discharge 
or HAPU incidence. Results of the Markov approach were age-adjusted and com-
pared to prior probabilities of HAPU risk derived from naïve and full Bayesian 
inference. Measures of computational accuracy and efficiency were derived to 
compare analytical approaches. Results: The EHR provided a panel of over 34,787 
patients. The Markov model yielded transition probabilities for each of 7 transi-
tions. Patient risk for developing a HAPU is highly predictable after approximately 
4-6 iterations. The very high-risk cohort had a clinically meaningful increase in 
risk for HAPU development of 2.35% compared to a minimal risk transition prob-
ability of 0.05% (p< 0.001). Neither of the Bayesian classifiers provided accurate 
comparisons. ConClusions: Real-world big data from an EHR enables outcomes 
researchers to mine transition probabilities using supervised machine learning. 
These results can be obtained to efficiently populate Markov models for cost-
effectiveness and decision analysis.
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objeCtives: Epilepsy lays an important burden on healthcare systems and 
society in general. Disability adjusted life years (DALYs) have been developed to 
compare the burden of this disease both between conditions and between geo-
graphical boundaries. With improving data on disease incidence and prevalence 
in Colombia, we can refine our DALYs-based estimates. Methods: Using different 
strategies, including the official healthcare provision database (called RIPS) and 
death certificates, as well as extrapolation from published neuroepidemiologic 
studies, we estimated the incidence and prevalence by age groups, the disease 
duration and the attributable mortality. Base don previous studies, we assumed 
an average disability weight of 0.113. With this information, and using the clas-
sic methodology described by Murray & Lopez, we calculated DALYs for the year 
2012. Results: 49,984 (10.4%) of the 479,836 Colombian epilepsy patients are 
in the 15-19 year-old group. Overall, it was found that epilepsy was responsible 
for 0.88% of all deaths (12,837) in Colombia, 8,219 (64%) of them in 60-year olds 
or older. A total of 5.25 DALYs per 1,000 person-years are lost due to epilepsy in 
Colombia, 75% of which (3.91 DALYs) are due to premature mortality, with a higher 
burden in men (6.12 DALYs) than in women (4.41 DALYs). ConClusions: We 
reported new estimations on epilepsy incidence and prevalence by age groups in 
Colombia and conclude that DALYs lost due to epilepsy in Colombia are almost 
double the previous figure, mostly because of the underestimation of attributable 
mortality. With this figure, epilepsy ranks 12th instead of 19th in the list of the 
most important causes of DALYs lost.
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